NASDAQ: GANX
Gain Therapeutics Inc Stock Ownership - Who owns Gain Therapeutics?

Insider buying vs selling

Have Gain Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Khalid IslamExecutive Chairman2024-08-0950,000$1.00
$49.95kBuy
Gene MacKCFO and Interim CEO2024-08-0914,400$1.01
$14.54kBuy
Eric I. RichmanDirector2024-07-0112,000$1.21
$14.52kBuy
Eric I. RichmanDirector2024-07-015,000$1.23
$6.15kBuy

1 of 1

GANX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when GANX insiders and whales buy or sell their stock.

GANX Shareholders

What type of owners hold Gain Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Khalid Islam3.35%930,784$1.75MInsider
Dme Capital Management LP2.04%566,130$1.06MInstitution
Eric I. Richman1.10%304,458$572.38kInsider
Geode Capital Management LLC0.96%267,421$502.75kInstitution
Vanguard Group Inc0.64%177,075$332.90kInstitution
Gotham Asset Management LLC0.57%158,155$297.33kInstitution
Jones Financial Companies LLLP0.35%98,250$184.71kInstitution
Marshall Wace LLP0.33%91,738$172.47kInstitution
Morgan Stanley0.32%88,512$166.40kInstitution
Blackrock Inc0.31%86,061$161.79kInstitution

1 of 3

GANX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
GANX7.14%4.69%Net Buying
KPTI63.18%36.82%Net SellingNet Selling
RENB13.94%73.07%Net Selling
MDCX11.21%47.64%
ARMP1.66%98.34%Net SellingNet Selling

Gain Therapeutics Stock Ownership FAQ

Who owns Gain Therapeutics?

Gain Therapeutics (NASDAQ: GANX) is owned by 7.14% institutional shareholders, 4.69% Gain Therapeutics insiders, and 88.17% retail investors. Khalid Islam is the largest individual Gain Therapeutics shareholder, owning 930,784.00 shares representing 3.35% of the company. Khalid Islam's Gain Therapeutics shares are currently valued at $1.91M.

If you're new to stock investing, here's how to buy Gain Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.